Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Taskinen

Showing results (311-320 of 318) with videos related to

Pageof 32
Sort By:
You have reached the last page of results.This site can display upto 318 results.
The Journal of Laboratory and Clinical Medicine|February 1, 1980
Apolipoprotein CII in type I hyperlipoproteinemia. A study in three casesM L Kashyap, L S Srivastava, R C Tsang, et al.
Atherosclerosis|September 23, 1997
Phenotype expression in familial combined hyperlipidemiaK V Porkka, I Nuotio, P Pajukanta, et al.
Lancet (London, England)|November 29, 2005
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialA Keech, R J Simes, P Barter, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|April 22, 2017
Fructose intervention for 12 weeks does not impair glycemic control or incretin hormone responses during oral glucose or mixed meal tests in obese menN Matikainen, S Söderlund, E Björnson, et al.
The Journal of Clinical Investigation|February 15, 1997
Characterization of the MODY3 phenotype. Early-onset diabetes caused by an insulin secretion defectM Lehto, T Tuomi, M M Mahtani, et al.
Lancet (London, England)|November 9, 2007
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trialA C Keech, P Mitchell, P A Summanen, et al.
Journal of Internal Medicine|May 27, 2017
Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesityM-R Taskinen, S Söderlund, L H Bogl, et al.
Journal of Internal Medicine|April 11, 2017
Intestinal alkaline phosphatase at the crossroad of intestinal health and disease - a putative role in type 1 diabetesM I Lassenius, C L Fogarty, M Blaut, et al.
Pageof 32

Showing results (311-320 of 318) with videos related to

Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 318 results.
The Journal of Laboratory and Clinical Medicine|February 1, 1980
Apolipoprotein CII in type I hyperlipoproteinemia. A study in three casesM L Kashyap, L S Srivastava, R C Tsang, et al.
Atherosclerosis|September 23, 1997
Phenotype expression in familial combined hyperlipidemiaK V Porkka, I Nuotio, P Pajukanta, et al.
Lancet (London, England)|November 29, 2005
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialA Keech, R J Simes, P Barter, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|April 22, 2017
Fructose intervention for 12 weeks does not impair glycemic control or incretin hormone responses during oral glucose or mixed meal tests in obese menN Matikainen, S Söderlund, E Björnson, et al.
The Journal of Clinical Investigation|February 15, 1997
Characterization of the MODY3 phenotype. Early-onset diabetes caused by an insulin secretion defectM Lehto, T Tuomi, M M Mahtani, et al.
Lancet (London, England)|November 9, 2007
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trialA C Keech, P Mitchell, P A Summanen, et al.
Journal of Internal Medicine|May 27, 2017
Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesityM-R Taskinen, S Söderlund, L H Bogl, et al.
Journal of Internal Medicine|April 11, 2017
Intestinal alkaline phosphatase at the crossroad of intestinal health and disease - a putative role in type 1 diabetesM I Lassenius, C L Fogarty, M Blaut, et al.
Pageof 32